News – Page 1110 – Endpoints News

What's worth $500M-plus? The Big 6 deals of Q2 show you where the money is — and isn't

8 years ago

Is Amazon planning to disrupt the $560B prescription drug market?

8 years ago

Trump's renewed broadsides on drug pricing didn't even dent biopharma this time

8 years ago

J&J beefs up neuro pipeline, bags a new depression drug from Cerecor in $45M deal

8 years ago

Cel-Sci shares jump after FDA lifts hold; New upstart is looking for Euro marketing pacts with biotech

8 years ago

In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure

8 years ago

Merck CEO Ken Frazier resigns from Trump council in protest, and the president swiftly bites back

8 years ago

Zynerba shares crushed (again) as back-to-back flops leave lead drug under a cloud

8 years ago

Focused on data and drug development, SoftBank hunts new $1B biotech deals — report

8 years ago

Mundipharma picks up a PhIII-ready chemo creation in $250M deal

8 years ago

Novartis partner Ophthotech says wet-AMD drug Fovista goes 0-for-3 in PhIII

8 years ago

Novartis veteran David Epstein takes leadership role at Rubius

8 years ago

Here's why Sucampo paid $200M for its PhIII Niemann-Pick drug

8 years ago

Peregrine slashes R&D in a reorg that claims 60 jobs; Zai Labs in hunt for $150M IPO - report

8 years ago

GSK abandons Ionis' FDA-ready inotersen as new CEO sweeps out rare disease efforts

8 years ago

Dicerna escalates war with Alnylam over RNAi secrets, claiming its rival wants a monopoly

8 years ago

Gilead circles February 12 on its calendar as D-day for its HIV franchise

8 years ago

Gushing red ink, biotech billionaire Soon-Shiong slashes staff at NantHealth by 300, sells assets

8 years ago

Takeda strikes a combo I/O discovery pact with Shattuck Labs; Facing FDA rejection, Egalet slashes staff

8 years ago

Apellis grabs $60M to pay for a looming PhIII showdown with Alexion's Soliris

8 years ago

UK’s Biotecnol strikes a deal with CRUK to move new immuno-oncology drug into PhI

8 years ago

Zealand bags a $77M IPO haul as investors embrace another biotech offering

8 years ago

Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA

8 years ago

Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?

8 years ago

First page Previous page 1107 1108 110911101111 1112 1113 Next page Last page